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Abstract
Eight new sulfide-based cyclic peptidomimetic analogues of solonamides A and B have been synthesized via solid-phase peptide
synthesis and SN2’ reaction on a Morita–Baylis–Hillman (MBH) residue introduced at the N-terminal of a tetrapeptide. This last
step takes advantage of the electrophilic feature of the MBH residue and represents a new cyclization strategy occurring. The ana-
logues were prepared in moderate overall yields and did not show toxic effects on Staphylococcus aureus growth and were not
toxic to human fibroblasts. Two of them inhibited the hemolytic activity of S. aureus, suggesting an interfering action in the bacte-
rial quorum sensing similar to the one already reported for solonamides.
Introduction
The cyclodepsipeptides called solonamides A and B are natural
molecules extracted from the marine bacterium Photobac-
terium halotolerans [1,2] (Figure 1). They are able to prevent
the expression of Staphylococcus aureus virulence factors such
as α-hemolysin and phenol-soluble modulins without affecting
the bacterial growth [3]. Particularly, solonamide B and its ana-
logues revealed no detectable toxicity against erythrocytes or
human neutrophils [3,4].
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Figure 1: Chemical structure of solonamides and autoinducing peptides (AIP).
Scheme 1: Macrocyclization strategy based on SN2’.
Staphylococcus aureus is an opportunistic Gram-positive
bacterium found in human commensal microbiota. Once epithe-
lial barriers or immune systems become compromised,
S. aureus can cause skin and soft tissue infections besides
severe invasive diseases such as endocarditis, pneumonia, and
septicemia [5-7]. In particular, methicillin-resistant S. aureus
(MRSA) is considered an endemic cause of nosocomial infec-
tions and has spread into the community and livestock animals
as well [8]. Expression of many S. aureus virulence factors is
controlled by a sophisticated intercellular chemical signalling
pathway named quorum-sensing (QS) circuit Agr (accessory
gene regulator) [8-11]. Four native thiolactonic cyclopeptides,
named autoinducing peptides (AIPs, Figure 1), were found to be
the chemical signals for the QS circuit Agr. Their chemical
structures are remarkably alike to solonamides, and the synthe-
sis of new molecules structurally related to these natural
peptidomimetics has been used as a promising strategy for the
attenuation of bacterial virulence in strains of S. aureus [12-15].
Herein, we report the synthesis of new sulfide-based cyclic
peptidomimetics through the allylic nucleophilic substitution
(SN2’) of cysteine sulfhydryl side chain to electrophilic Cβ of
an O-acetylated Morita–Baylis–Hillman (MBH) adduct residue
(Scheme 1). Despite reports describing the use of amino acid
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Scheme 2: Chemical synthesis of the MBH adducts 2 and their carboxylic acids 3.
residues with nucleophilic side chains to prompt the macrocy-
clization of peptides and their mimetics, to the best of our
knowledge, this is the first report on the participation of MBH
residues as electrophilic sites to allow an SN2’-based macrocy-
clization of peptidomimetics [16-30]. Two of these new com-
pounds were able to interfere with the hemolytic activity of
S. aureus, and since the hemolysin expression is activated by
S. aureus QS, we can suppose that the reported activity may be
related to the inhibition of this bacterial communication system.
Results and Discussion
Rational design and synthesis of the
solonamide analogues
The rational design of our solonamide analogues was based on
the conservation of the 16-membered macrocyclic scaffold and
the apolar tripeptidyl moiety found in the solonamides. Both
features are important to guarantee the interference with
S. aureus QS [12-15]. The ester linkage of the lactone core was
substituted by the sulfide group. Cyclic thioether peptides have
been found in the chemical skeletons of natural products and
synthetic ones that display a wide variety of activities, includ-
ing antibiotics [31], vascular cell adhesion molecule-1 antago-
nists [32] and anticardiolipin antibodies [33,34].
Two MBH adducts (2) (R = Me, heptyl) and their respective
carboxylic acids 3 were obtained in good yields based on previ-
ously reported procedures (Scheme 2) [35,36].
Starting from Rink Amide AM resin-bound orthogonally pro-
tected Fmoc-Cys-(Trt) 4, solonamide analogues were synthe-
sized following stepwise Fmoc deprotection and standard repet-
itive Fmoc-amino acid couplings yielding the linear resin-bound
tetrapeptides 5 (Scheme 3) [37,38]. The MBH acids 3 were
coupled to the free amine at the N-terminal of 5 to afford the
resin-bound linear peptidomimetics 6, which subsequently had
the hydroxy group of the MBH residue acylated with acetic an-
hydride to yield 7. Despite the good results for the acetylation
of peptides 6 with R = Me at room temperature, the reaction of
the ones with R = n-hexyl needed to be conducted under heat
conditions (50 °C). Acidic treatment of the acetates 7 with tri-
fluoroacetic acid: triisopropylsilane decoupling cocktail
afforded the resin-free linear peptidomimetics 8.
Scheme 3: Chemical synthesis of the linear peptidomimetics 8.
The SN2’ macrocyclization step was performed immediately
after the cleavage procedure to avoid the oxidative disulfide
dimerization observed when preparative HPLC purification of
the resin-free linear peptidomimetics 8 was tried. Thus, a 1 mM
solution of peptides 8 in dry THF/CH2Cl2 (1:1) containing Et3N
was vigorously stirred for 48 h at room temperature (Scheme 4)
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Scheme 4: Macrocyclization strategy based on SN2’ reaction to affords the solonamide analogues 9 and their overall yields based on the initial resin’s
molarity.
as previously described in a similar procedure for the intermo-
lecular SN2’ reaction between thiophenol and O-acetylated
MBH adducts [39]. The solonamide analogues 9 were obtained
after preparative HPLC purification and lyophilization. The
overall yield for this 11-step synthesis ranged from 7% to 15%
for almost all solonamide analogues 9, based on the initial
resin’s molarity. The exception relays on those containing ᴅ-Ala
and ʟ-Leu amino acid residues sequentially attached to an ʟ-Cys
residue, which were obtained in yields lower than 5%. We
ascribed this result to the steric strains imposed by the spatial
accommodation of these amino acid residue side chains on the
resin-free linear peptidomimetics 8, which seems to disfavour
the approximation of the nucleophilic sulfhydryl group to the
electrophilic MBH residue.
Spectral characterization of the chemical
structures of the solonamide analogues 9
The compounds were characterized by one- and two-dimen-
sional NMR spectroscopy, infrared spectroscopy (IR) and mass
spectrometry. The high-resolution MS/MS analysis allowed the
observation of a fragmentation pattern that does not coincide
with the one found in linear peptides, where we would observe
the loss of the ʟ-Cys residue. In addition to the sequential loss
of ammonia (17 amu) and CO (28 amu) to yield the iminium
[M − NH3 − CO]+ (Schemes S4–S11, Supporting Information
File 1), as expected for the C-terminal carboxamide, we ob-
served three ions derived from the breaking of two amide
bonds, starting from the opening of the macrocycle by the loss
of one, two or three amino acid residues as neutral fragments.
This fragmentation pattern agrees with the one expected for
cyclic peptides [40]. Noteworthy, the detected ions A–C always
showed the –SCH2CH=NH moiety, confirming the formation of
the sulfide group (Schemes S4–S11, Supporting Information
File 1).
The NMR experiments also confirmed the macrocyclic struc-
ture (Supporting Information File 1). The 1H NMR spectra of
compounds 9 had the characteristic signal in δ 3.2–3.6 ppm,
resonating as a dd, assigned to C1 methylene protons
(Scheme 4); this signal only changes in the multiplicity for
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compounds 9g and 9h that is presented as a broad singlet. Addi-
tionally, we observed another signal around δ 5.8–6.5 ppm, that
depending on the compound can be a q or t, integrating for one
hydrogen, assigned to C3 methine hydrogen. The 1H,13C-
HMBC spectra allows us to observe an important strong corre-
lation between the signals assigned to the protons on C1 and the
carbon Cβ of the cysteine, which strongly suggest the forma-
tion of the new C–S bond. The configuration of the double bond
could be assigned as Z for all compounds due to the 1H,1H-
NOESY correlations between the C3 hydrogen and the NH
hydrogen of the amino acid residue attached to the adduct
residue.
The IR spectra of analogues 9 were quite similar (Supporting
Information File 1). Three main absorption bands could be
readily observed around 3280, 1650 and 1520 cm−1. The first
one was assigned to the stretch for N–H bonds of the peptide
linkage. The stretch for the lactam and lactone C=O bonds gives
rise to the broad absorption close to 1650 cm−1. The lowering
on the wavenumber values for the lactone C=O stretch was also
observed for bands assigned to the C=C bonds as consequence
of their conjugation.
Evaluation of the growth inhibition and
hemolytic activity of S. aureus for the
solonamide analogues
Initially, the antibacterial activity of all analogues 9 was tested
by determining the minimum inhibitory concentration against
two antibiotic-susceptible reference strains of S. aureus,
S. aureus ATCC 25923 and S. aureus ATCC 29213 (see Sup-
porting Information File 1, assay 1) [41]. Two-fold serial dilu-
tions were performed, allowing to test several concentrations
within the range of 300–0.3 µM. None of the compounds
presented antibacterial activity against S. aureus, since no MIC
value could be obtained in the range of concentrations tested
(MIC > 300 µM).
Subsequently, a screening assay was carried out to evaluate the
effect of these compounds on the hemolysis of defibrinated
sheep blood promoted by S. aureus ATCC 25923, a strain that
produces hemolysins under the control of QS (see Supporting
Information File 1, assay 2) [42]. Among all compounds, 9e and
9g showed the best results, inhibiting the hemolytic activity of
S. aureus at lower concentrations (Table 1 and Figure 2). Ana-
logues 9e and 9g were then tested at lower concentrations
(300–5 µM), and 9e was able to hamper the hemolysis by the
strain at 10 µM (see Supporting Information File 1, Table S1).
The antihemolytic activity of 9e and 9g was also tested in a
quantitative microdilution assay using human red blood cells
(see Supporting Information File 1, assay 3) [43]. Analogue 9e
Table 1: Halos of hemolysis or inhibition of hemolysis of S. aureus
ATCC 25923 on sheep blood agar plates (Assay 2).a
Analogue 20 mM 1 mM 200 μM
9a + + +
9b + + +
9c + + +
9d + + +
9e – – –
9f + + +
9g – +* +*
9h – + +
a(+): Hemolysis halo; (–): no hemolysis halo; *visibly smaller hemol-
ysis halo when compared to controls.
Figure 2: Effect of compounds 9e and 9g at three concentrations on
the hemolysis production by S. aureus ATCC 25923 (Assay 2, Inoc =
inoculum). Regarding compound 9e, no hemolysis halo was observed
around the bacterial spot.
showed better capacity to inhibit the hemolysis than 9g at the
same concentration (Figure 3). At concentrations of 10 µM and
200 µM of 9e, the hemolysis production by S. aureus was in-
hibited by 63% and 84%, respectively.
Also, a cell viability assay on human fibroblasts (Detroit 551
cell line) was performed for compounds 9e and 9g in order to
observe their eventual cytotoxicity to normal cells (see Support-
ing Information File 1, assay 4). The concentration range tested
was 6.25 to 200 µM for 9e and 9.38 to 300 µM for 9g, chosen
based on the optimal dose observed in the hemolysis inhibition
assay. We observed that these two compounds did not affect the
fibroblast viability in the concentrations tested (Figure 4).
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Figure 4: Cell viability of human fibroblast exposed to compounds 9e (A) and 9g (B) for 24 and 48 hours. The values are expressed as mean ± SEM.
****p < 0.0001, **p < 0.005 and ***p < 0.001 versus DMEM control group.
Figure 3: Inhibition of hemolysis (%) on human red blood cells caused
by S. aureus ATCC 25923 after being in presence of several concen-
trations of compounds 9e and 9g (assay 3). The hemolysis is scored in
% of hemolysis relative to the control (hemolysis caused by S. aureus
ATCC 25923 in absence of any compound; only DMSO), which was
set to 100%. Two independent experiments were performed in dupli-
cate. Error bars represent standard deviations.
Furthermore, no statistically significant difference was ob-
served between exposition times of 24 and 48 h. These data
suggest that 9e and 9g are not toxic to normal cells within the
tested experimental conditions.
Solonamide B has been shown to inhibit agr-controlled pheno-
types in S. aureus (including hemolysis) at concentrations
ranging between 8.5 µM and 17 µM [3]. Similar inhibitory con-
centrations (10 to 20 µM) were displayed by our analogues, 9e
and 9g, with the advantage that sulfide linkage is less prompted
to hydrolysis than the ester found at solonamides [44,45].
Comparing the chemical structure of analogues 9e–g and 9h to
the previously reported analogues of solonamides and S. aureus
AIPs, some observations can be made: (1) 9e is the only one
among all the analogues derived from the acetaldehyde adduct
that, regardless of the configuration of the stereogenic centres,
has the same amino acid residue sequence found in solon-
amides; (2) despite the close similarity on the amino acid
residue sequence displayed by 9e and 9h, the stereochemistry of
the Phe residue is detrimental to the antihemolytic activity;
(3) in a similar sense, for 9f and 9g, diastereosiomers on the Ile
residue, the L-configuration on this residue is necessary to the
observed hemolysis inhibition by S. aureus.
Conclusion
A new, effective and simple cyclization strategy using MBH
adducts for the preparation of eight new sulfide-based cyclic
peptidomimetics structurally similar to solonamides was estab-
lished. Two of these new compounds had the capacity to inhibit
the hemolytic activity of S. aureus ATCC 25923 without
affecting its growth, at very low concentrations, namely 10 μM,
and were not cytotoxic to human fibroblasts at the same con-
centration. Due to the well-known relationship of the
α-hemolysins expression with the accessory gene regulator
(agr) of the S. aureus, we can suggest that these two peptido-
mimetics may exert an effect on S. aureus quorum sensing. To
evaluate this hypothesis, we are now rationally designing new
solonamide analogues, based on the SN2’ strategy reported
here, to be tested for AgrC-inhibitory activity.
Supporting Information
Supporting Information File 1
Detailed synthetic procedures, biological assay procedures
and copies of NMR and MS spectra of all compounds.
[https://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-15-247-S1.pdf]
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